DE69428984D1 - Stimulierung der immunantwort durch virales protein - Google Patents

Stimulierung der immunantwort durch virales protein

Info

Publication number
DE69428984D1
DE69428984D1 DE69428984T DE69428984T DE69428984D1 DE 69428984 D1 DE69428984 D1 DE 69428984D1 DE 69428984 T DE69428984 T DE 69428984T DE 69428984 T DE69428984 T DE 69428984T DE 69428984 D1 DE69428984 D1 DE 69428984D1
Authority
DE
Germany
Prior art keywords
protein
peptide
immune response
viral protein
protein immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69428984T
Other languages
English (en)
Other versions
DE69428984T2 (de
Inventor
Christian Ertel
Hoegen Paul Von
Volker Schirrmacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69428984D1 publication Critical patent/DE69428984D1/de
Publication of DE69428984T2 publication Critical patent/DE69428984T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69428984T 1993-03-16 1994-03-11 Stimulierung der immunantwort durch virales protein Expired - Fee Related DE69428984T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93301962 1993-03-16
PCT/GB1994/000476 WO1994021798A1 (en) 1993-03-16 1994-03-11 Stimulation of immune response by viral protein

Publications (2)

Publication Number Publication Date
DE69428984D1 true DE69428984D1 (de) 2001-12-13
DE69428984T2 DE69428984T2 (de) 2002-08-14

Family

ID=8214340

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428984T Expired - Fee Related DE69428984T2 (de) 1993-03-16 1994-03-11 Stimulierung der immunantwort durch virales protein

Country Status (9)

Country Link
EP (1) EP0689596B1 (de)
JP (1) JPH08508641A (de)
KR (1) KR960701208A (de)
AT (1) ATE208421T1 (de)
AU (1) AU675703B2 (de)
CA (1) CA2158461A1 (de)
DE (1) DE69428984T2 (de)
WO (1) WO1994021798A1 (de)
ZA (1) ZA941853B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236271T1 (de) 1993-04-30 2003-04-15 Wellstat Biologics Corp Verwendung der ndv zur herstellung eines medikaments zur krebsbehandlung
DE4407538C1 (de) * 1994-03-07 1995-02-23 Deutsches Krebsforsch Bindungsreagens für Zell-Oberflächenprotein und Effektorzelle
US6093700A (en) 1995-05-11 2000-07-25 Thomas Jefferson University Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
DE69535288T2 (de) * 1994-05-13 2007-04-05 Thomas Jefferson University Verfahren zur induzierung einer immunantwort mittels rekombinanten vaccinia-viren, die das gm-csf-gen exprimieren
EP1092439A1 (de) * 1999-10-13 2001-04-18 Thorsten Dr. Ahlert Aktivierung antigen-spezifischer T-Zellen mit Virus/Antigen-behandelten dendritischen Zellen
WO2003103707A1 (en) 2002-06-06 2003-12-18 Immunicum Ab New method and composition for producing a cellular allogeneic vaccine
JP4855250B2 (ja) * 2004-03-31 2012-01-18 ジェノミディア株式会社 抗腫瘍作用を有する組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
FR2663228A2 (fr) * 1989-09-29 1991-12-20 Agronomique Inst Nat Rech Composition immunisante contre la maladie de newcastle et procede de preparation.

Also Published As

Publication number Publication date
ZA941853B (en) 1995-09-18
KR960701208A (ko) 1996-02-24
AU675703B2 (en) 1997-02-13
ATE208421T1 (de) 2001-11-15
AU6247794A (en) 1994-10-11
DE69428984T2 (de) 2002-08-14
JPH08508641A (ja) 1996-09-17
EP0689596A1 (de) 1996-01-03
EP0689596B1 (de) 2001-11-07
WO1994021798A1 (en) 1994-09-29
CA2158461A1 (en) 1994-09-29

Similar Documents

Publication Publication Date Title
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
ATE334216T1 (de) Impstoff gegen felines immunodefizienz-virus
DK0538437T3 (da) Immunstimulerende og immunforstærkende, rekonstituerede influenzavirosomer og vacciner indeholdende dem
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
ATE141946T1 (de) Hiv-2-virusvarianten
AP2000001841A0 (en) Method for obtaining vaccines for preventing the pathgenic effects related to a retroviral infection.
BR9202024A (pt) Virus de apivox recombinante,cultura de celulas eucariotica infectadas por um virus de avipox,vacina,sequencia de transferencia e plasmideo
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
FR2669346B1 (fr) Vaccin a poxvirus recombinant contre le virus de la rougeole.
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
ATE134195T1 (de) Peptidfragmente von hiv
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
AU6683400A (en) Vaccine against lentiviral infections, such as the feline immune deficiency virus of the cat
ATE109158T1 (de) Rubella-e1 und c peptide.
ATE346087T1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
ES2160594T3 (es) Antigenos protectores contra la infeccion por echinococcus granulosus y vacunas que contienen estos antigenos.
SE9202934D0 (sv) Vacciner mot melanom
AR020852A1 (es) Antigenos de vacuna de leptospira para la prevencion de leptospirosis
NZ331889A (en) Trypanosomatids histones for use as an antigen against trypanosomatic infection, including diagnostic tests, pharmaceutical compositions and vaccines of these antigens
ATE102252T1 (de) Rekombinantes gefluegelpockenvirus, expressionsvektoren fuer heterologische proteine und davon derivierte gefluegelvakzine.
NL300254I1 (nl) Verzwakte herpesvirussen, herpesvirussen die vreemd DNA omvatten dat codeert voor een aminozuur-sequentie en vaccin dat het bevat.
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee